{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:10:21Z","timestamp":1790399421627,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that is spreading rapidly, which seriously impacts global public health and economy. Thus, developing effective drugs remains urgent. We identify two potent antibodies, nCoVmab1 and nCoVmab2, targeting the SARS-CoV-2 spike protein receptor-binding domain (RBD) with high affinities from a na\u00efve human phage-displayed Fab library. nCoVmab1 and nCoVmab2 neutralize authentic SARS-CoV-2 with picomolar and nanomolar IC<jats:sub>50<\/jats:sub> values, respectively. No detectable defects of nCoVmab1 and nCoVmab2 are found during the preliminary druggability evaluation. nCoVmab1 could reduce viral titer and lung injury when administered prophylactically and therapeutically in human angiotensin-converting enzyme II (hACE2)-transgenic mice. Therefore, phage display platform could be efficiently used for rapid development of neutralizing monoclonal antibodies (nmabs) with clinical potential against emerging infectious diseases. In addition, we determinate epitopes in RBD of these antibodies to elucidate the neutralizing mechanism. We also convert nCoVmab1 and nCoVmab2 to their germline formats for further analysis, which reveals the contribution of somatic hypermutation (SHM) during nCoVmab1 and nCoVmab2 maturation. Our findings not only provide two highly potent nmabs against SARS-CoV-2 as prophylactic and therapeutic candidates, but also give some clues for development of anti-SARS-CoV-2 agents (e.g., drugs and vaccines) targeting the RBD.<\/jats:p>","DOI":"10.1038\/s41467-021-25153-x","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T10:10:36Z","timestamp":1628503836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics"],"prefix":"10.1038","volume":"12","author":[{"given":"Shaojuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglou","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yancheng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0389-3011","authenticated-orcid":false,"given":"Xiaoqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rendi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8089-163X","authenticated-orcid":false,"given":"Zhengli","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9222-5642","authenticated-orcid":false,"given":"Rui","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"key":"25153_CR1","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","author":"Coronaviridae Study Group of the International Committee on Taxonomy of V.","year":"2020","unstructured":"Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536\u2013544 (2020).","journal-title":"Nat. Microbiol."},{"key":"25153_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"25153_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"25153_CR4","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"25153_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221\u2013224 (2020).","journal-title":"Nature"},{"key":"25153_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281\u2013292 e286 (2020).","journal-title":"Cell"},{"key":"25153_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrmicro2090","volume":"7","author":"L Du","year":"2009","unstructured":"Du, L. et al. The spike protein of SARS-CoV\u2013a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226\u2013236 (2009).","journal-title":"Nat. Rev. Microbiol."},{"key":"25153_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/14728222.2017.1271415","volume":"21","author":"L Du","year":"2017","unstructured":"Du, L. et al. MERS-CoV spike protein: a key target for antivirals. Expert Opin. Ther. Targets 21, 131\u2013143 (2017).","journal-title":"Expert Opin. Ther. Targets"},{"key":"25153_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12250-013-3313-x","volume":"28","author":"Z Zhu","year":"2013","unstructured":"Zhu, Z. et al. Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1. Virol. Sin. 28, 71\u201380 (2013).","journal-title":"Virol. Sin."},{"key":"25153_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"25153_CR11","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","volume":"181","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181, 894\u2013904 e899 (2020).","journal-title":"Cell"},{"key":"25153_CR12","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827 e819 (2020).","journal-title":"Cell"},{"key":"25153_CR13","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1021\/acsmedchemlett.0c00410","volume":"11","author":"A Fernandez","year":"2020","unstructured":"Fernandez, A. Structural impact of mutation D614G in SARS-CoV-2 spike protein: enhanced infectivity and therapeutic opportunity. ACS Med. Chem. Lett. 11, 1667\u20131670 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"25153_CR14","doi-asserted-by":"crossref","unstructured":"Mansbach, R. A. et al. The SARS-CoV-2 Spike variant D614G favors an open conformational state. Sci. Adv. 7, eabf3671 (2021).","DOI":"10.1126\/sciadv.abf3671"},{"key":"25153_CR15","doi-asserted-by":"publisher","first-page":"e1241","DOI":"10.1002\/cti2.1241","volume":"10","author":"CY Lee","year":"2021","unstructured":"Lee, C. Y. et al. Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant. Clin. Transl. Immunol. 10, e1241 (2021).","journal-title":"Clin. Transl. Immunol."},{"key":"25153_CR16","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1373\/clinchem.2004.038422","volume":"50","author":"M Fenger","year":"2004","unstructured":"Fenger, M. et al. Detection of antinuclear antibodies by solid-phase immunoassays and immunofluorescence analysis. Clin. Chem. 50, 2141\u20132147 (2004).","journal-title":"Clin. Chem."},{"key":"25153_CR17","doi-asserted-by":"publisher","first-page":"10892","DOI":"10.1128\/JVI.75.22.10892-10905.2001","volume":"75","author":"MB Zwick","year":"2001","unstructured":"Zwick, M. B. et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75, 10892\u201310905 (2001).","journal-title":"J. Virol."},{"key":"25153_CR18","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1126\/science.1111781","volume":"308","author":"BF Haynes","year":"2005","unstructured":"Haynes, B. F. et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906\u20131908 (2005).","journal-title":"Science"},{"key":"25153_CR19","doi-asserted-by":"crossref","unstructured":"Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327\u20131335\u00a0(2020).","DOI":"10.1038\/s41590-020-0778-2"},{"key":"25153_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","volume":"182","author":"RD Jiang","year":"2020","unstructured":"Jiang, R. D. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 50\u201358 e58 (2020).","journal-title":"Cell"},{"key":"25153_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120\u2013124 (2020).","journal-title":"Nature"},{"key":"25153_CR22","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","volume":"368","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274\u20131278 (2020).","journal-title":"Science"},{"key":"25153_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19231-9","volume":"11","author":"NK Hurlburt","year":"2020","unstructured":"Hurlburt, N. K. et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. Nat. Commun. 11, 5413 (2020).","journal-title":"Nat. Commun."},{"key":"25153_CR24","doi-asserted-by":"publisher","first-page":"W503","DOI":"10.1093\/nar\/gkn316","volume":"36","author":"X Brochet","year":"2008","unstructured":"Brochet, X., Lefranc, M. P. & Giudicelli, V. IMGT\/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36, W503\u2013W508 (2008).","journal-title":"Nucleic Acids Res."},{"key":"25153_CR25","first-page":"695","volume":"2011","author":"V Giudicelli","year":"2011","unstructured":"Giudicelli, V., Brochet, X. & Lefranc, M. P. IMGT\/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb. Protoc. 2011, 695\u2013715 (2011).","journal-title":"Cold Spring Harb. Protoc."},{"key":"25153_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20501-9","volume":"12","author":"J Ge","year":"2021","unstructured":"Ge, J. et al. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Nat. Commun. 12, 250 (2021).","journal-title":"Nat. Commun."},{"key":"25153_CR27","doi-asserted-by":"crossref","unstructured":"Bertoglio, F. et al. A SARA-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Rep 36, 109433 (2021).","DOI":"10.1016\/j.celrep.2021.109433"},{"key":"25153_CR28","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.abc7520","volume":"369","author":"TF Rogers","year":"2020","unstructured":"Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956\u2013963 (2020).","journal-title":"Science"},{"key":"25153_CR29","doi-asserted-by":"publisher","first-page":"108274","DOI":"10.1016\/j.celrep.2020.108274","volume":"33","author":"NC Wu","year":"2020","unstructured":"Wu, N. C. et al. An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain. Cell Rep. 33, 108274 (2020).","journal-title":"Cell Rep."},{"key":"25153_CR30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","volume":"182","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell 182, 828\u2013842 e816 (2020).","journal-title":"Cell"},{"key":"25153_CR31","doi-asserted-by":"crossref","unstructured":"Jiang, S., Zhang, X. & Du, L. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. Expert Opin. Ther. Targets 1\u20137 (2020).","DOI":"10.1080\/14728222.2020.1820482"},{"key":"25153_CR32","doi-asserted-by":"publisher","first-page":"1854149","DOI":"10.1080\/19420862.2020.1854149","volume":"12","author":"M Tuccori","year":"2020","unstructured":"Tuccori, M. et al. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs 12, 1854149 (2020).","journal-title":"MAbs"},{"key":"25153_CR33","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jama.2021.0202","volume":"325","author":"RL Gottlieb","year":"2021","unstructured":"Gottlieb, R. L. et al. Effect of Bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 325, 632\u2013644 (2021).","journal-title":"JAMA"},{"key":"25153_CR34","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. 384, 238\u2013251 (2021).","journal-title":"N. Engl. J. Med."},{"key":"25153_CR35","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/22221751.2019.1624482","volume":"8","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Antibodies and vaccines against Middle East respiratory syndrome coronavirus. Emerg. Microbes Infect. 8, 841\u2013856 (2019).","journal-title":"Emerg. Microbes Infect."},{"key":"25153_CR36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/rmv.706","volume":"22","author":"MM Coughlin","year":"2012","unstructured":"Coughlin, M. M. & Prabhakar, B. S. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev. Med. Virol. 22, 2\u201317 (2012).","journal-title":"Rev. Med. Virol."},{"key":"25153_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9223","volume":"6","author":"T Ying","year":"2015","unstructured":"Ying, T. et al. Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat. Commun. 6, 8223 (2015).","journal-title":"Nat. Commun."},{"key":"25153_CR38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.celrep.2018.06.041","volume":"24","author":"S Zhang","year":"2018","unstructured":"Zhang, S. et al. Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein. Cell Rep. 24, 441\u2013452 (2018).","journal-title":"Cell Rep."},{"key":"25153_CR39","doi-asserted-by":"publisher","first-page":"104868","DOI":"10.1016\/j.antiviral.2020.104868","volume":"182","author":"X Pan","year":"2020","unstructured":"Pan, X. et al. Immunoglobulin fragment F(ab\u2019)2 against RBD potently neutralizes SARS-CoV-2 in vitro. Antivir. Res. 182, 104868 (2020).","journal-title":"Antivir. Res."},{"key":"25153_CR40","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"L Dai","year":"2020","unstructured":"Dai, L. et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 182, 722\u2013733 e711 (2020).","journal-title":"Cell"},{"key":"25153_CR41","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","volume":"397","author":"P Richmond","year":"2021","unstructured":"Richmond, P. et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet 397, 682\u2013694 (2021).","journal-title":"Lancet"},{"key":"25153_CR42","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech, C. et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 383, 2320\u20132332 (2020).","journal-title":"N. Engl. J. Med."},{"key":"25153_CR43","doi-asserted-by":"crossref","unstructured":"Yang, S. et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis 21, 1107\u20131119 (2021).","DOI":"10.1016\/S1473-3099(21)00127-4"},{"key":"25153_CR44","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/eji.201445017","volume":"45","author":"K Dallenbach","year":"2015","unstructured":"Dallenbach, K. et al. Protective effect of a germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease. Eur. J. Immunol. 45, 1238\u20131247 (2015).","journal-title":"Eur. J. Immunol."},{"key":"25153_CR45","doi-asserted-by":"crossref","unstructured":"Schrade, A. et al. Back-to-Germline (B2G) procedure for antibody devolution. Antibodies 8, 45 (2019).","DOI":"10.3390\/antib8030045"},{"key":"25153_CR46","doi-asserted-by":"publisher","first-page":"19127","DOI":"10.1074\/jbc.RA118.005367","volume":"293","author":"F Zeng","year":"2018","unstructured":"Zeng, F. et al. Comprehensive elucidation of the structural and functional roles of engineered disulfide bonds in antibody Fc fragment. J. Biol. Chem. 293, 19127\u201319135 (2018).","journal-title":"J. Biol. Chem."},{"key":"25153_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/978-1-59745-554-1_6","volume":"525","author":"Z Zhu","year":"2009","unstructured":"Zhu, Z. & Dimitrov, D. S. Construction of a large naive human phage-displayed Fab library through one-step cloning. Methods Mol. Biol. 525, 129\u2013142, xv (2009).","journal-title":"Methods Mol. Biol."},{"key":"25153_CR48","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","volume":"169","author":"MA Whitt","year":"2010","unstructured":"Whitt, M. A. Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 169, 365\u2013374 (2010).","journal-title":"J. Virol. Methods"},{"key":"25153_CR49","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1006\/viro.1993.1575","volume":"197","author":"D Navarro","year":"1993","unstructured":"Navarro, D. et al. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology 197, 143\u2013158 (1993).","journal-title":"Virology"},{"key":"25153_CR50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269\u2013271 (2020).","journal-title":"Cell Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25153-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25153-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25153-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T13:55:56Z","timestamp":1669989356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25153-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["25153"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-25153-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,9]]},"assertion":[{"value":"4 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.G., S.Z., H.Z., X.Z., Z.Z., H.Z., Y.Z., C.P., and X.G. are inventors on CN patent application: 202010599355.2. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4887"}}